A Phase 1b, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine When Administered to Adults, and

Project: Research project

Project Details

StatusActive
Effective start/end date2/12/20 → 2/11/25

Funding

  • ModernaTX, Inc: $8,772.00